An ideal prognostic test for estrogen receptor-positive breast cancer?

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4058-4059

  Paik, Soonmyung ^a   Tang, Gong ^b   Fumagalli, Debora ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ALGORITHM; BREAST CANCER; CANCER RECURRENCE; CHEMOTHERAPY; EDITORIAL; FOLLOW UP; GENETIC VARIABILITY; HEALTH INSURANCE; MATHEMATICAL COMPUTING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION;

ALGORITHMS; BREAST NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PROGNOSIS; RECEPTORS, ESTROGEN; RISK; THERAPY, COMPUTER-ASSISTED;

EID: 51649121333     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7528     Document Type: Editorial

References (12)

1. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
2. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
3. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
4. Goldstein L, Gray R, Badveet S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
5. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
6. Cobleigh MA, Tabesh B, Bitterman P, et al: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11:8623-8631, 2005
7. Habel LA, Shak S, Jacobs MK, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
8. Simon JA, Szankasi P, Nguyen DK, et al: Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 60:328-333, 2000
9. Amat S, Penault-Llorca F, Cure H, et al: Scarff-Bloom-Richardson (SBR) grading: A pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791-796, 2002
10. Boiesen P, Bendahl PO, Anagnostaki L, et al: Histologic grading in breast cancer- reproducibility between seven pathologic departments: South Sweden Breast Cancer Group. Acta Oncol 39:41-45, 2000
11. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
12. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006